Some antiseizure medicines can make hormonal contraception less effective, while some hormonal contraceptives can change antiseizure medicine levels. The interaction can work in either direction, and the safest contraceptive choice depends on the exact epilepsy medicine being used.
This is why contraception in epilepsy should not be treated as a separate issue from seizure treatment. A change in antiseizure medicine can alter contraceptive reliability, and a change in hormonal contraception can alter seizure control or medicine side effects.
There are two main types of interaction
The first is when an antiseizure medicine increases the activity of liver enzymes that break down contraceptive hormones. This can lower hormone concentrations and make some contraceptives less reliable.
The second is the reverse: a hormonal contraceptive changes the concentration of an antiseizure medicine. The best-known example is lamotrigine, whose concentration can fall substantially when oestrogen-containing contraception is started.
Enzyme-inducing antiseizure medicines
Some antiseizure medicines increase the activity of hepatic enzymes, particularly cytochrome P450 enzymes. This can accelerate the breakdown of oestrogens and progestogens used in hormonal contraception.
Medicines commonly recognised as enzyme inducers include:
- carbamazepine
- phenytoin
- phenobarbital
- primidone
- oxcarbazepine
- eslicarbazepine acetate
- rufinamide
- topiramate, where the interaction depends on dose and product-specific advice
Not every antiseizure medicine is an enzyme inducer. Levetiracetam, gabapentin, pregabalin and valproate, for example, do not normally reduce contraceptive hormone concentrations through this mechanism.
Why enzyme induction matters
If contraceptive hormone concentrations fall far enough, ovulation may no longer be reliably suppressed or cervical mucus may not remain sufficiently hostile to sperm. The result is an increased risk of contraceptive failure.
This is not necessarily visible. Breakthrough bleeding can occur, but the absence of bleeding does not prove that contraceptive hormone levels remain adequate.
Combined hormonal contraception
Combined hormonal contraception includes the combined oral contraceptive pill, the contraceptive patch and the vaginal ring. These contain an oestrogen together with a progestogen.
Enzyme-inducing antiseizure medicines can reduce the effectiveness of combined hormonal contraception. Specialist contraceptive guidance therefore generally recommends choosing a method that is not affected by enzyme induction rather than simply assuming a standard combined pill will remain reliable.
Historic practice sometimes used higher-dose combined pills with enzyme-inducing medicines, but current guidance increasingly favours methods that avoid the interaction altogether because contraceptive protection is more predictable.
Progestogen-only pills
Enzyme-inducing antiseizure medicines can also reduce the effectiveness of progestogen-only pills. The interaction applies because the contraceptive relies on systemic progestogen concentrations.
Someone taking an enzyme inducer should not assume that switching from a combined pill to a progestogen-only pill automatically solves the problem.
The contraceptive implant
The etonogestrel contraceptive implant is highly effective in people who are not taking interacting medicines. However, enzyme-inducing medicines can increase the breakdown of etonogestrel and reduce contraceptive effectiveness.
For long-term use of an enzyme-inducing antiseizure medicine, the implant is therefore usually not the preferred method if pregnancy prevention needs to be highly reliable.
Depot medroxyprogesterone acetate injection
The progestogen-only injectable contraceptive depot medroxyprogesterone acetate, often called DMPA, is not considered to lose contraceptive effectiveness because of hepatic enzyme-inducing medicines.
This makes it one option for people taking enzyme-inducing antiseizure medicines, although its own advantages and disadvantages still need to be considered, including bleeding pattern, delayed return to fertility after stopping and effects on bone mineral density.
Bone health is particularly relevant because some antiseizure medicines are themselves associated with reduced bone mineral density. Contraceptive choice should therefore take the whole clinical picture into account.
Hormonal intrauterine system
A levonorgestrel-releasing intrauterine system acts mainly within the uterus and its contraceptive effectiveness is not reduced by enzyme-inducing antiseizure medicines.
For many people requiring highly reliable contraception while taking an enzyme inducer, this is one of the methods that can avoid the interaction.
Copper intrauterine device
A copper intrauterine device contains no hormone, so antiseizure medicines do not reduce its contraceptive effectiveness.
It is one of the most effective reversible contraceptive methods and also has an important role in emergency contraception.
Lamotrigine is different
Lamotrigine illustrates why contraception and epilepsy medicines cannot be discussed only in terms of contraceptive failure.
Lamotrigine is not a significant hepatic enzyme inducer in the way carbamazepine or phenytoin are. The major established interaction runs in the opposite direction: oestrogen-containing contraception can increase lamotrigine metabolism and substantially reduce lamotrigine blood concentrations.
This can lead to loss of seizure control in some people.
What happens during the pill-free interval?
With a conventional combined pill regimen, lamotrigine concentrations can fall while active oestrogen-containing pills are taken and then rise again during the hormone-free interval.
This creates two possible problems: reduced seizure protection during the active-pill phase and higher lamotrigine exposure, with potential side effects, during the break.
Starting or stopping combined hormonal contraception can therefore require specialist review of the lamotrigine dose and, in selected cases, blood-level monitoring.
Symptoms of changing lamotrigine levels
Falling lamotrigine levels may be associated with breakthrough seizures or return of auras. Rising levels can cause dose-related adverse effects such as dizziness, double vision, blurred vision, imbalance, nausea or other neurological symptoms.
These symptoms are not specific to lamotrigine toxicity, but a recent change in contraception is an important clue that should not be overlooked.
Does lamotrigine reduce contraceptive effectiveness?
The evidence here is less clear. Lamotrigine is not considered a conventional enzyme inducer, but small pharmacokinetic studies have found modest changes in levonorgestrel exposure. The clinical significance for contraceptive failure is uncertain.
Because of this uncertainty, people taking lamotrigine should receive individual contraceptive advice rather than assuming every hormonal method is interchangeable.
Topiramate needs special attention
Topiramate can interact with some hormonal contraceptives, and the degree of enzyme induction is dose dependent. Product-specific advice matters.
In the UK, the interaction has become particularly important because topiramate is subject to a Pregnancy Prevention Programme for women and girls who can become pregnant.
The MHRA requires highly effective contraception during topiramate treatment and for at least four weeks after the last dose. Pregnancy must be excluded before treatment begins, and the reproductive risks must be reviewed regularly.
Because topiramate itself may make some hormonal methods less reliable, contraceptive choice should be checked with the prescriber, pharmacist or specialist contraception service rather than selected without reference to the epilepsy treatment.
Valproate and contraception
Valproate is not an enzyme-inducing antiseizure medicine, so it does not usually reduce hormonal contraceptive concentrations in the way carbamazepine or phenytoin can.
However, valproate has major reproductive safety restrictions because exposure during pregnancy is associated with substantial risks of congenital malformations and neurodevelopmental impairment.
In the UK, women and girls who are able to become pregnant must not be treated with valproate unless the conditions of the Pregnancy Prevention Programme are met and other treatment options are unsuitable.
Highly effective contraception, specialist review and documented discussion of risk are central parts of that programme.
The contraceptive method itself does not treat the epilepsy
Hormonal contraception may alter seizure patterns in some individuals, especially where seizures show hormonal sensitivity, but it should not be described as a general treatment for epilepsy.
The priority remains selecting a contraceptive method that is reliable, acceptable and compatible with the antiseizure medicine regimen.
Catamenial epilepsy does not create one universal contraceptive rule
People with catamenial seizure patterns may notice changes when hormonal contraception is started, stopped or changed, but responses vary.
Some methods suppress ovulation more consistently than others. Even so, there is not enough evidence to say that one contraceptive universally improves seizure control in catamenial epilepsy.
Seizure-cycle recording can help identify whether a change in contraception coincides with a meaningful change in seizure frequency.
Emergency contraception and enzyme-inducing medicines
Enzyme-inducing antiseizure medicines can reduce the effectiveness of oral emergency contraception.
FSRH guidance recommends offering a copper intrauterine device where appropriate because it is the most effective form of emergency contraception and is not affected by enzyme induction.
If a copper IUD is not suitable or accepted, a 3 mg dose of levonorgestrel emergency contraception can be considered for people using enzyme-inducing medicines, but the effectiveness of this doubled oral dose is uncertain.
Doubling the dose of ulipristal acetate emergency contraception is not recommended.
Recent enzyme-inducer use can still matter
Enzyme induction does not disappear immediately when a medicine is stopped. The effect can persist while enzyme activity returns toward baseline.
That means contraception and emergency contraception advice may need to account for recently stopped enzyme-inducing treatment as well as medicines currently being taken.
Starting an enzyme-inducing antiseizure medicine
If someone is already using hormonal contraception and an enzyme-inducing antiseizure medicine is added, contraceptive protection should be reviewed promptly.
Do not assume the existing method remains adequate simply because it was effective before the epilepsy medicine changed.
A pharmacist, GP, epilepsy clinician or sexual-health specialist can check whether the current method is affected and whether an unaffected method or temporary additional contraception is needed.
Stopping an enzyme inducer also deserves review
Stopping an enzyme-inducing medicine can increase the concentrations of other drugs whose metabolism had previously been accelerated.
Although the major concern with contraception is usually loss of contraceptive effectiveness during enzyme induction, medication changes can affect several interacting treatments at once. A planned review is preferable to making multiple unsupervised changes.
Changing contraception while taking lamotrigine
Starting an oestrogen-containing contraceptive can lower lamotrigine concentrations. Stopping it can allow lamotrigine concentrations to rise.
This means even a change made for ordinary contraceptive reasons — for example changing pill type, stopping the pill to try for pregnancy or moving to another method — can require epilepsy medication review.
It is particularly important not to stop contraception suddenly in someone taking a medicine with major pregnancy risks without first making a coordinated plan.
Contraception failure should not be treated as a moral or adherence issue
Drug interactions can cause contraceptive failure even when a contraceptive has been used correctly.
People with epilepsy should therefore be told clearly whether their antiseizure medicine can reduce contraceptive effectiveness. This information needs to be revisited whenever medication changes, not given once and then assumed to remain valid indefinitely.
Which methods are least affected by enzyme induction?
Methods whose contraceptive effectiveness is not reduced by hepatic enzyme-inducing antiseizure medicines include:
- copper intrauterine devices
- levonorgestrel intrauterine systems
- depot medroxyprogesterone acetate injection
Barrier methods are also not altered pharmacologically, but their contraceptive effectiveness depends strongly on correct and consistent use and they may not meet the requirements of a Pregnancy Prevention Programme when used alone.
Highly effective contraception and Pregnancy Prevention Programmes
The phrase highly effective contraception has a specific safety purpose when a medicine can cause serious harm in pregnancy.
For medicines such as valproate and topiramate, UK regulatory requirements are stricter than simply advising someone to “use contraception”. The aim is to use a method or combination of methods with very low failure risk and to ensure that the person understands the reproductive risk of the medicine.
The exact regulatory requirements can change. Current MHRA materials and specialist advice should therefore be checked rather than relying on an old leaflet or an earlier prescription discussion.
Contraception before puberty and during adolescence
NICE recommends discussing future reproductive risks with girls who may still require antiseizure treatment when they become able to have children.
This does not mean assuming sexual activity. It means making sure medicine choices made in childhood or adolescence are not allowed to continue into reproductive years without appropriate review and information.
Contraception after pregnancy
Fertility can return before the first postnatal period. People who do not want another pregnancy immediately should therefore discuss contraception as part of postnatal epilepsy care.
The choice must take account of breastfeeding, thrombosis risk, the antiseizure medicine being used, and any postpartum changes in drug dose.
If pregnancy occurs while taking an antiseizure medicine
A suspected or confirmed pregnancy needs prompt clinical review, but antiseizure medication should not usually be stopped suddenly.
Abrupt withdrawal can cause seizure recurrence, including prolonged or bilateral tonic-clonic seizures, which can create serious risks for both the pregnant person and pregnancy.
For topiramate used for epilepsy, the MHRA specifically advises urgent review rather than abrupt self-discontinuation. Valproate should also never be stopped without specialist advice.
Questions worth asking at a contraception review
- Is my antiseizure medicine an enzyme inducer?
- Can it reduce the effectiveness of my current contraception?
- Can my contraception change the blood level of my antiseizure medicine?
- Does my medicine carry a major pregnancy risk?
- Do I need a Pregnancy Prevention Programme?
- What should I do if I miss contraception or need emergency contraception?
- Will changing or stopping contraception require an antiseizure medicine dose review?
- Who should I contact if I am planning pregnancy?
The central message
There is no single “epilepsy-safe contraceptive”. The correct choice depends on the exact antiseizure medicine, the contraceptive method and the person’s own medical and reproductive priorities.
The most important interaction patterns are straightforward once identified: enzyme-inducing antiseizure medicines can reduce the effectiveness of several systemic hormonal contraceptives, while oestrogen-containing contraception can lower lamotrigine concentrations.
For people taking valproate or topiramate, contraception is also part of formal reproductive-risk management in the UK.
Whenever an antiseizure medicine or hormonal contraceptive is started, stopped or substantially changed, the interaction should be checked again.
Related pages: Hormones, Contraception & Pregnancy · Catamenial Epilepsy · Breastfeeding and Antiseizure Medicines · Medication Side Effects and Interactions · Treatment Options
Sources and further reading
NICE NG217 — Principles of treatment, safety, monitoring and withdrawal
NICE NG217 — Information and support: reproductive health and pregnancy
Faculty of Sexual & Reproductive Healthcare — Drug Interactions with Hormonal Contraception
FSRH — Combined Hormonal Contraception guideline
FSRH — Emergency Contraception guideline
MHRA — Topiramate: Pregnancy Prevention Programme and safety measures
MHRA — Valproate reproductive risks
MHRA — Antiepileptic drugs in pregnancy: updated safety advice
NHS — Lamotrigine: interactions including hormonal contraception
Evidence checked: September 2026.